Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Caparello C, Turrini M, Rossi V, Ciccone LP, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E.
Tibaldi C, et al. Among authors: mazzoni f.
Anticancer Agents Med Chem. 2022;22(7):1278-1285. doi: 10.2174/1871520621666210727112212.
Anticancer Agents Med Chem. 2022.
PMID: 34315390